Snake venom phospholipase A2 (PLA2) that shows high presynaptic neurotoxicity in vertebrata that is independent of catalytic activity (PubMed:2544597, PubMed:10548416 and PubMed:16669624), as well as local myotoxicity when intramuscularly injected into mice (PubMed:16669624). Blocks acetylcholine release in Aplysia neurons (PubMed:8583413), and potentiates pro-inflammatory cellular signaling (PubMed:12782627). Potentiates glutamate excitoxicity when coinjected into brain of rats (PubMed:10548416). May act by binding in a calcium-dependent fashion and with high affinity to a neuronal-type (N-type) PLA2 receptor, and with very high affinity to a muscle-type (M-type) PLA2 receptor. In vitro, shows a high-specific activity on E.coli membranes and is more efficient on the anionic phospholipid POPG than on the anionic phospholipid POPS or the zwitterionic phospholipid POPC. Exerts catalytically-independent anti-HIV (IC(50) is 35 nM) activity and catalytically-dependent antimalarial activity (IC(50) is 3.1 nM when tested on P.falciparum grown in serum that contains lipoproteins). PLA2 catalyzes the calcium-dependent hydrolysis of the 2-acyl groups in 3-sn-phosphoglycerides. a 1,2-diacyl-sn-glycero-3-phosphocholine + H2O = a 1-acyl-sn-glycero-3-phosphocholine + a fatty acid + H(+) Binds 1 Ca(2+) ion. Monomer. Expressed by the venom gland. LD(100) is 2 ug/kg by intracerebroventricular injection into mice. Belongs to the phospholipase A2 family. Group I subfamily. D49 sub-subfamily.